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Mean estimates of the difference in cost and patients
treated to target (PTT) were used to establish the optimal
adoption decision. The uncertainty surrounding this deci-
sion was characterised by estimating cost-effectiveness
acceptability curves and the associated frontier. Sensitiv-
ity analysis assessed the robustness of the results to alter-
native scenarios including: baseline cholesterol levels,
dosage regimens and the availability of signiﬁcantly dis-
counted generic simvastatin. RESULTS: Rosuvastatin is
demonstrated to dominate (i.e. lower costs and a higher
number of PTT) atorvastatin, simvastatin, and pravas-
tatin. Compared to ﬂuvastatin, the incremental cost per
additional PTT of rosuvastatin was £24 using LDL-C and
£83 using TC. The probability that rosuvastatin is cost-
effective exceeds 95% provided the NHS is prepared to
pay at least £35 per PTT to achieve target LDL-C cho-
lesterol levels (£160 for TC). These results were demon-
strated to be robust to all scenarios examined in the
sensitivity analysis. CONCLUSIONS: The analysis
demonstrates that rosuvastatin is more cost-effective than
the other statins in achieving European cholesterol
targets.
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OBJECTIVES: Antiplatelet therapy, following acute
stroke, has been shown to have preventative efﬁcacy
against serious vascular events, including: recurrent
stroke, transient ischaemic attack, and myocardial infarc-
tion. We used a Markov model approach to consider 
the relative cost-effectiveness of alternative antiplatelet
therapies compared to standard low-dose aspirin.
METHODS: An existing Markov model was updated
with UK-speciﬁc data on expected health care resource
usage and unit costs, and was used to consider levels of
recurrent stroke-related events, and their associated cost
implications, over periods of time of up to 25-years after
an acute stroke event. Underlying risks were derived from
the placebo-control arm of the ESPS-2 study (Years 1–2
of the model), and the community-based Oxford Com-
munity Stroke Project (Years 3–5 of the model). Beyond
Year 5, risks were based on an age-matched cohort from
the OCSP data. Relative risks for active treatments were
derived from the ESPS-2 study for both Asasantin Retard
and low-dose aspirin, and the CAPRIE study for clopi-
dogrel. Estimates of expected resource usage were based
on feedback on a structured questionnaire survey of UK-
based clinicians. RESULTS: When compared to low-dose
aspirin, Asasantin Retard provided additional beneﬁts
(29 avoided recurrent strokes per 1,000 treated patients
over a 5-year period) for an additional cost of approxi-
mately £66,000 (a cost per avoided stroke of £2,249). A
probabilistic Monte carlo sensitivity analysis based on
background placebo-level risks, relative risk for Asasan-
tin Retard, costs of an acute stroke and costs of long-term
care suggested that a 95% likelihood of the cost per
avoided stroke value falling below £14,000. Asasantin
Retard had lower treatment-related cost and avoided
more recurrent stroke events than clopidogrel in the mod-
elled 5-year analysis. CONCLUSIONS: Our modelled
analysis suggests that Asasantin Retard is a cost-effective
treatment compared to standard low-dose aspirin in
avoiding acute recurrent stroke-related events.
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OBJECTIVE: To estimate the excess cost of stroke in
Sweden, and potential cost offsets by preventing the
occurrence of ﬁrst-ever stroke. METHODS: We adopted
the incidence approach for estimating the present value
of both direct- and indirect costs. Data on mortality,
stroke recurrence and inpatient care were estimated from
a national register of patient data with a 4-year follow-
up period. To estimate costs for social services we used
registered data on living conditions before stroke onset,
and at 3 and 24 months. Costs for outpatient visits, reha-
bilitation, drugs and production losses due to premature
death and early retirement are estimated on the basis of
both published and non-published sources. Lifetime costs
are extrapolated from year ﬁve and for subsequent years
adjusted by age, gender and excess mortality for stroke.
RESULTS: With an incidence of 17,000 ﬁrst-ever strokes
in Sweden (195/100,000 individuals), the total excess
direct and indirect cost of stroke is SEK9.5 billion
(approximately US$1.2 billion or €1.0 billion) in year
2000 prices. About SEK7.4 billion is direct costs and
SEK2.1 billion indirect costs. Half of the direct costs are
costs for social services. The present value direct cost for
an average stroke patient is SEK434,000 (US$54,250 
or €48,740) and the indirect cost is SEK125,000
(US$15,600 or €13,750). CONCLUSIONS: There are
large potential cost offsets both in the health care sector
and in the social service sector if the incidence of ﬁrst-
ever stroke could be reduced.
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OBJECTIVES: Patients undergoing surgery for hip frac-
ture are in the highest category of risk for postoperative
venous thromboembolism, but data on thromboprophy-
laxis in these patients were scarce. Fondaparinux, a new
synthetic selective factor Xa inhibitor proved to be more
effective than enoxaparin in preventing venous throm-
boembolism in these patients and was equally safe. We
evaluated its cost-effectiveness relative to enoxaparin 
over a period of ﬁve years post-surgery. METHODS: We
modelled the impact of fondaparinux based on 7-day 
prophylaxis on patient outcomes and costs to the UK
National Health Service (NHS). Outcomes are throm-
boembolic events (symptomatic deep vein thrombosis,
pulmonary embolism), and long term complications
(recurrences, post thrombotice syndrome), and death.
Probabilities for efﬁcacy and safety outcomes were
derived from randomised clinical trials comparing enoxa-
parin with fondaparinux, and from a review of the liter-
ature. Resource consequences were estimated from a
survey of UK hospitals and a panel of clinical experts.
Costs were estimated using mean national costs to the
NHS. RESULTS: In a hypothetical cohort of 1000
patients, fondaparinux is estimated to prevent 23 addi-
tional thromboembolic events (clinical VTE) and 6 deaths
compared to enoxaparin, with savings fully compensat-
ing added costs of prophylaxis by day 30 (break-even
point). Total savings for the cohort would be £29,000 at
5 years. These ﬁndings are robust to wide variations in
key assumptions in the model. CONCLUSIONS: Com-
pared with enoxaparin, fondaparinux is a cost-effective
and dominant strategy in prophylaxis against venous
thromboembolism following hip fracture surgery. Bene-
ﬁts of using fondaparinux begin early following surgery,
with savings increasing over time.
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OBJECTIVE: The PCI-CURE study demonstrated that
clopidogrel compared to placebo, both groups receiving
standard therapy including ASA reduces the risk of major
cardiovascular events in patients with ACS undergoing
PCI. The purpose of this analysis was to evaluate the cost
per event avoided in Austria, Belgium, Italy, Spain, and
Switzerland. METHODS: The composite outcome used
for the cost-effectiveness analysis was the difference in
occurrences of all cardiovascular deaths, myocardial
infarctions, and strokes. Costs of hospitalization, pro-
cedures, comedications and study drug were calculated
based on resource utilization reported for all patients
undergoing PCI in the CURE study. Hospitalization 
costs were evaluated through a Diagnosis Related Group
approach in all countries. Unit costs were developed in
each country and applied to all patients of the CURE
study. Cost-effectiveness was expressed as the cost per
event avoided, in analogy with previously published eval-
uations in this area. The time horizon was that of the 
clinical trial (12 months). RESULTS: The occurrence of
the composite outcome was signiﬁcantly lower in the
clopidogrel arm compared to placebo (11.65% versus
15.17%). For every 1000 patients treated with clopido-
grel 35 additional atherothrombotic events were avoided.
The total cost of managing a patient with ACS undergo-
ing PCI ranged from €5,728 to €13,604 in the placebo
arm depending on the country. This cost was increased
by +1.2% to +4.9% in the clopidogrel arm. The cost 
of clopidogrel was partly offset by savings due to less
severe main diagnosis during hospitalizations. The incre-
mental cost per patient ranged from €166 to €390. This
resulted in a cost per cardiovascular event avoided
ranging from €4,732 to €11,065, which is better com-
pared to other interventions in this area. CONCLUSION:
Clopidogrel in patients with ACS undergoing a PCI is
cost-effective and results are very consistent across 
European countries.
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OBJECTIVES: To identify and to explain the possible dif-
ferences in resource use for the treatment of chronic heart
failure (CHF) in France (F), Germany (G), Italy (I), the
Netherlands (NL), Spain (S), and the United Kingdom
(UK). METHODS: MAHLER was a multi-centric obser-
vational (non-interventional) study on the medical man-
agement, the health care resource use and the cost of
CHF. A total of 1421 NYHA (New York Heart Associa-
tion) class II to IV patients were included and were
prospectively followed over 6 months. The frequencies of
patients using a speciﬁc resource and the mean number
of uses were computed for each country. Predictors of
